Video

Dr. Marshall on Genetic Testing in Gastrointestinal Cancer

John L. Marshall, MD, discusses the evolution of genetic testing in gastrointestinal cancer.

John L. Marshall, MD, chief, Hematology and Oncology, professor, medicine and oncology, director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the evolution of genetic testing in gastrointestinal cancer.

Although genetic testing can identify individual gene mutations, science and technology have evolved to include next-generation sequencing, which uses a large piece of tissue to look for more genes at one time, Marshall says. A more advanced form of testing that warrants further understanding is proteome analysis, which requires a larger, higher-quality tissue sample, Marshall explains.

When considering liquid biopsy, blood testing that is not tissue enriched can be effective, but not in all patients, Marshall notes. For those patients whose mutations do not appear in their blood alone, tissue-enriched blood testing allows for a deeper exploration of potential mutations based on sequencing from a tumor, Marshall says. Like other forms of genetic testing, liquid biopsy is evolving, and both types of blood tests have distinct clinical roles, Marshall concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity